[Anti-TA226 human monoclonal antibody (ACA-11) against glioma].
A human monoclonal antibody (ACA-11) against TA226 reacted with various glioma tissues, but did not react with normal brain tissues. TA226 was expressed on glioma cells and not detected in serum and cerebrospinal fluid. ACA-11 exhibited antibody-dependent cell cytotoxicity against glioma cells. Half life in serum concentration of ACA-11 in glioma patients was 75.33 hours. Phase II study of ACA-11 was performed against 111 cases of glioma. 1 mg of ACA-11 was administrated once or twice/week during 24 weeks. Overall response rate was 24.2% (16/66). Mild adverse reaction was found in 10 cases (9.2%). In conclusion, the specific immunotherapy using human monoclonal antibody, ACA-11, is safe and effective therapy in patients with glioma.
Kokunai
Takashi
T
Department of Neurosurgery, Kakogawa Municipal Hospital.
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000276:immunology*; D001932:Brain Neoplasms / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D005910:Glioma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm